We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Huntsworth Plc | LSE:HNT | London | Ordinary Share | GB00B0CRWK29 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 107.50 | 107.50 | 108.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMHNT
RNS Number : 7707Z
Huntsworth PLC
19 December 2017
19 December 2017
Huntsworth plc
(Huntsworth or the Company)
Board Changes
The Board of Huntsworth, the international healthcare communications and public relations group, is pleased to announce a number of changes to the membership of its Board of Directors and Committees, all to be effective from 1 January 2018.
Appointment of Non-Executive Director
Liz McKee Anderson will join the Board of Directors of Huntsworth plc as an independent non-executive director.
Liz has extensive experience in the pharmaceuticals industry, notably having held a number of senior executive roles at Johnson & Johnson. Since April 2017, Liz has been a Board Director of Bavarian Nordic A/S, a biotechnology company listed on the Danish stock exchange. Liz is also an Independent Board Director of Revolution Medicines, Inc. She holds a number of other positions in both commercial and non-profit spheres, including the Wistar Institute. Liz holds an MBA from Loyola University and has a degree in Engineering. Liz will be a member of the Company's Audit Committee.
Derek Mapp, Chairman of Huntsworth said:
"I am delighted that we have managed to recruit a very high calibre individual to the Board with extensive experience in the pharmaceutical and biotechnology industries. These industries are of increasing importance to Huntsworth as can be seen with the growth and significance of the Huntsworth Health business."
Appointment of Senior Independent Director
Andy Boland will be appointed as Huntsworth's Senior Independent Director. Andy has been a director of Huntsworth plc since 11 August 2014, has previously served as the chair of the Audit Committee and remains as a member of both the Audit and Nomination Committees.
Committee Membership
The membership of Huntsworth's Committees will be:
Audit Committee: Pat Billingham (Chair) Liz McKee Anderson Andy Boland Nicky Dulieu Nomination Committee: Derek Mapp (Chair) Pat Billingham Andy Boland Nicky Dulieu Remuneration Committee: Nicky Dulieu (Chair) Pat Billingham
Enquiries to:
Citigate Dewe Rogerson +44 (0)20 7638 9571 Angharad Couch Elizabeth Kittle Nick Reading
Additional information:
There is no further information to be disclosed in accordance with paragraph 9.6.13 of the Listing Rules of the UK Listing Authority.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAZMMMZLLVGNZG
(END) Dow Jones Newswires
December 19, 2017 04:27 ET (09:27 GMT)
1 Year Huntsworth Chart |
1 Month Huntsworth Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions